Compare VLN & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VLN | KRRO |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.8M | 187.9M |
| IPO Year | 2021 | 2019 |
| Metric | VLN | KRRO |
|---|---|---|
| Price | $1.72 | $12.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $3.00 | ★ $34.80 |
| AVG Volume (30 Days) | ★ 784.5K | 71.4K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,392,000.00 |
| Revenue This Year | $8.37 | N/A |
| Revenue Next Year | $16.99 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 181.46 |
| 52 Week Low | $1.10 | $5.20 |
| 52 Week High | $3.71 | $55.89 |
| Indicator | VLN | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 41.78 | 37.94 |
| Support Level | $1.40 | $9.76 |
| Resistance Level | $1.76 | $14.42 |
| Average True Range (ATR) | 0.09 | 0.77 |
| MACD | -0.01 | -0.21 |
| Stochastic Oscillator | 7.14 | 6.93 |
Valens Semiconductor Ltd is a provider of semiconductor products, pushing the boundaries of connectivity by enabling long-reach, high-speed video, and data transmission for the audio-video and automotive industries. It operates in two segments: Cross Industry Business, which includes solutions for the non-automotive verticals, including audio-video, industrial, machine vision and medical markets, that deliver superior, plug-and-play convergence and distribution of different interfaces, through a single long-distance category cable; and Automotive segment products enable safe and resilient high-speed in-vehicle connectivity for car architectures, realizing the vision of connected and autonomous cars. The company's geographical revenue is derived from Hungary.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.